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Background and aims: Impaired insulin secretion plays a key role in the development of cystic fibrosis-related diabetes (CFDR). Numerous
indices to evaluate insulin secretion have been proposed, but their validity has not been explored in cystic fibrosis (CF). The aim of the present
study was to validate surrogate indices of insulin secretion in CF patients against the gold standard, the intravenous glucose tolerance test
(IVGTT).
Methods: 32 subjects were enrolled: 16 controls, 10 cystic fibrosis-normal glucose tolerant (CF-NGT) and 6 CFRD patients. All subjects
underwent a 2-h oral glucose tolerance test (OGTT) and an IVGTT. Insulin secretion was estimated using three indices: the HOMA-β cell, the
Stumvoll's early insulin secretion, and the insulin secretion rate (ISR).
Results: In control subjects, all insulin secretion indices correlated significantly with the IVGTT. In CF-NGT patients, the HOMA-β cell
correlated significantly with the IVGTT at shorter time points but not over longer time-period. On the other hand, both OGTT-derived indices
(Stumvoll and IRS) correlated significantly with the IVGTT for the CF-NGT and CFRD groups.
Conclusion: Since the OGTT is required on a regular basis in CF patients to screen for CFRD, OGTT-derived indices appear to be suitable for
evaluating insulin secretion.
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Cystic fibrosis (CF) is an autosomal recessive disease
characterized by chronic lung infection as well as chronic
malabsorption secondary to pancreatic insufficiency [1]. With
increased life expectancy, glucose tolerance abnormalities are
now highly prevalent, with up to 40% of adults diagnosed with
CF-related diabetes (CFRD) and 35% with impaired glucose
tolerance (IGT) [2–5]. Diabetes occurrence is associated with
increased mortality and morbidity [5–7]. Insulin deficiency can⁎ Corresponding author. Institut de recherches cliniques de Montréal, 110
avenue des Pins Ouest, Montréal, Qc, Canada H2W 1R7.
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doi:10.1016/j.jcf.2009.08.007be detected in the vast majority of patients including patients
with normal glucose tolerance (NGT) or IGT [8,9]. Deteriora-
tion of insulin secretion is believed to be the primary cause of
CFRD [4,8,10].
Numerous indices derived from fasting or oral glucose
tolerance test (OGTT) values have been proposed to evaluate
insulin secretion [11–13]. However, the etiology of CFRD is
different from that of type 1 and type 2 diabetes [14,15].
Therefore, it is important to validate insulin secretion indices in
this population. Thus, the aim of the present study was to
validate insulin secretion indices against the intravenous
glucose tolerance test (IVGTT), the gold standard to measure
insulin secretion [16], in a control population and in CF
patients, including subjects with CFRD. We selected three
indices, a fasting-derived index: the homeostasis model assess-
ment (HOMA)-β cell [17], and two OGTT-derived indices: thed by Elsevier B.V. All rights reserved.
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cose metabolism in CF is mainly characterized by postprandial
abnormalities [3,19], we hypothesized thatOGTT-derived indices
would be more accurate than fasting based indices.2. Methods
2.1. Subjects
Sixteen adult (N18 years of age) CF patients and 16 controls
with NGT matched for age and sex participated in this study.
The protocol was approved by the Research Ethics Committee
of the Centre hospitalier de l'Université de Montréal (CHUM),
and all subjects signed a written consent form. The CF patients
included in the study had either normal glucose tolerance (CF-
NGT) or CFRD based on the OGTT. Diagnosis of CFRD was
based either on two consecutive abnormal OGTT values
(fasting values N7.0 mmol/L or 2 hN11.0 mmol/L) or if they
were on antidiabetic medication. To reduce the confounding
effect of treatment, CFRD patients were included only if they
were controlled by diet alone or if they could discontinue oral
hypoglycemic agents for at least 24 h without significant
impairment in diabetes control, (fasting glycemia b7 mmol/L).
The exclusion criteria were respiratory exacerbation in the
previous month, according to criteria published by the 1994
Cystic Fibrosis Foundation Microbiology and Infectious
Disease Consensus Conference [20]. Exacerbation was identi-
fied by a trained CF pneumologist on the day of the study.Table 12.2. CF status
Pulmonary function was measured by spirometry on the day
of the OGTT, using force expiratory volume (FEV)1 (L/s) and
predicted %FEV1 (Medgraphic 1870, St-Paul, MN, USA) as
variables. Genotype status was extracted from the medical files.
Pancreatic insufficiency was defined by current enzyme
supplementation.Insulin secretion formulae's.
Indices Formulas
IVGTT
First-phase insulin
response
Sum of insulin values at 0+4 min
or at (2+4) min
or at (0+4+6) min
or at (2+4+6) min
Insulin area under the
curve (AUC)
0–4 min
0–10 min2.3. Oral glucose tolerance test
After an overnight fast, all subjects ingested, in less than 5 min,
a glucose solution: 1.75 g/kg of body weight to a maximum of
75 g according toAmericanDiabetesAssociation guidelines [21].
Blood samples were taken at time 0, 30, 60, 90 and 120 min to
measure plasma glucose and insulin concentrations.Acute insulin response
(AIR)
Mean Ins at times (2, 4, 6 min) or
(0, 4, 6 min)− fasting Ins
Fasting based index
HOMA-β cell (20×Ins0 (mU/L)) / (Glyc0 (mmol/L)−3.5)
OGTT-derived indices
Insulin secretion rate
(ISR)
(Ins30− Ins0) (mU/L) / (Gly30−Gly0) (mg/dl)
Stumvoll's early insulin
secretion
1.283+1.829×Ins30 (pmol/L)−138.7×Glyc30
(mmol/L)+3.772×Ins0 (pmol/L)
Ins: insulin; Glyc: glycemia.2.4. Intravenous glucose tolerance test
The study began at 7:30 AM after overnight fasting. An
intravenous bolus of 20% glucose (0.3 g/kg of body weight)
was infused at time 0 over 2 min. Blood samples for the
measurement of plasma glucose and insulin were obtained at
−10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50 and 60 min to calculate
insulin secretion indices [16]. The IVGTT was done on a
separate day then the OGTT.2.5. Evaluation of insulin secretion
The following insulin secretion indices were evaluated: a
fasting-derived index: the HOMA-β cell, calculated according
to the formula described by Matthews et al. [17] and two
OGTT-derived indices: the Stumvoll's early insulin secretion
and the ISR [11,18]. These indices were compared to dynamic
measures of insulin secretion as determined with IVGTT values
and calculated as described in Table 1.
2.6. Biochemical dosages
Glucose and insulin levels were measured in duplicate.
Plasma glucose was determined at the time of sampling with a
Glucose Analyser (Beckman, Fullerton, CA, USA). Insulin
levels were measured by radio-immunoassay (Linco Research
Inc, St-Charles, MO, USA).
2.7. Statistical analysis
The data are presented as means±SE. Correlations were
calculated by Pearson's test. One-way ANOVA was performed
to analyze mean differences between the groups. When
significant differences were found, a Tukey post hoc test was
used to identify group differences. Significance was accepted at
Pb0.05.
3. Results
3.1. Characteristics of CF patients
This study included 16 CF patients: 10 CF-NGT and 6
CFRD with a mean diabetes duration 1–3 years as well as 16
healthy controls matched for age and sex (59% male, 41%
female). As shown in Table 2, all control subjects were NGT.
CFRD, but not CF-NGT patients, had lower body weight and
Table 2
Physical characteristics of control and CF subjects.
Controls CF-NGT CFRD
N=16 N=10 N=6
Age (years) 24.8±4.2 28.5±10.5 27.0±8.6
Sex ratio (M/F) 9/7 6/4 4/2
Weight (Kg) 66.78±9.10 64.63±11.66 56.80±10.67⁎
Body mass index 22.4±1.6 23.5±2.2 20.7±3.5⁎
Fasting glucose (mmol/L) 5.00±0.53 5.31±0.37 6.16±0.94⁎¥
Fasting insulin (μU/ml) 13.35±6.65 10.27±4.34 9.45±3.77
2-h OGTT glucose (mmol/L) 4.76±1.15 5.76±0.88 12.40±1.84⁎¥
2 h OGTT insulin (μU/ml) 39.85±22.01 47.94±48.59 45.29±15.12
OGTT: oral glucose tolerance test; CF-NGT: Cystic fibrosis-normal glucose
tolerance; CFDR: cystic fibrosis-related diabetes.
*Pb0.05 CFRD Vs controls.
¥Pb0.05 CFRD Vs CF-NGT.
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patients presented higher fasting and postprandial plasma
glucose levels compared to controls (Pb0.05) and CF-NGT
(Pb0.05). On the other hand, we observed no significant
differences between the three groups for insulin levels in both
the fasting state and 2 h after the OGTT.
3.2. Comparison of early phase insulin secretion indices with
dynamic insulin secretion measurements by the IVGTT
There is no consensus on the best indices to examine early
insulin secretion [11,22]. Therefore, we tested different
formulas to calculate early insulin secretion from the IVGTT
technique (Table 1). Values obtained from the IVGTT were
correlated with indices derived from fasting (HOMA-β cell) or
OGTT values (Stumvoll and ISR). In control subjects, all
surrogate indices of insulin secretion correlated significantly
with IVGTT values (Table 3). In CF-NGT patients, the HOMA-
β cell correlated significantly with the IVGTT at shorter time
points (0–4 min) but not when insulin secretion was examined
over longer time-period. On the other hand, both OGTT-derivedTable 3
Correlation between fasting and OGTT-derived early insulin secretion indices and f
Indices Groups IVGTT indices
0–4 min
HOMA-β cell (fasting) Controls r=0.64 ⁎
CF total r=0.76 ⁎⁎
CF-NGT r=0.70 ⁎
CFRD r=0.89 ⁎
ISR (OGTT) Controls r=0.49 ⁎
CF total r=0.77 ⁎⁎
CF-NGT r=0.80 ⁎
CFRD r=0.86 ⁎
Stumvoll (OGTT) Controls r=0.62 ⁎
CF total r=0.67 ⁎⁎
CF-NGT r=0.63; P=0.06
CFRD r=0.90 ⁎
OGTT: oral glucose tolerance test; CF-NGT: Cystic fibrosis-normal glucose toleran
intravenous glucose tolerance test.
⁎ Pb0.05.
⁎⁎ Pb0.01.indices correlated significantly with the IVGTT for CF patients,
including NGT and CFRD groups (Table 3).
4. Discussion
We, and others, have shown that CF is associated with
glucose abnormality including higher glucose excursion during
the OGTT even in CF-NGT subjects and that it is paralleled by
reduced early insulin secretion [3,23–25]. Furthermore, pro-
gression toward diabetes was associated with further reduction
in insulin secretion [4,24,25]. Thus, measurement of insulin
secretion is essential to enhance our understanding of the
pathogenesis and progression of CFRD. Because CFRD
presents an etiology distinct from either type 1 or type 2
diabetes, it is important to validate insulin secretion indices in
this population. Simple methods to assess insulin secretion are
important to evaluate the natural history and to dissect
pathophysiological mechanisms involved in CF occurrence.
Values from fasting or OGTT, which are required on a regular
basis in CF patients to screen for diabetes, are available and can
be used to evaluate insulin secretion in larger cohorts. The
objective of this study was to establish the validity of surrogate
indices for the evaluation of insulin secretion in CF patients.
Our study demonstrated that most surrogate indices of
insulin secretion correlated significantly with dynamic mea-
surements calculated from the IVGTT. It should be noted,
however, that for CF-NGT patients, the HOMA-β cell did not
perform as well as other indices when insulin secretion was
calculated over a longer time-period (see Table 3). Because the
HOMA-β cell index relies on fasting insulin values, while CF
patients mostly present stimulated insulin secretion abnormal-
ities, a fasting-based index may not accurately estimate the
reduced early insulin secretion observed in CF subjects. It has
been shown that the HOMA-β cell underestimates pancreatic
dysfunction in subjects with IGT and early-stage, asymptomatic
type 2 diabetic patients [26]. Studies show that the first measure
to become abnormal and/or deficient is first-phase insulinirst-phase insulin secretion measured with the IVGTT.
0–4–6 min AUC 0–10 min Air 0, 4, 6 min
r=0.68 ⁎ r=0.69 ⁎ r=0.64 ⁎
r=0.67 ⁎⁎ r=0.65 ⁎⁎ r=0.51
r=0.34 r=0.51 r=0.43
r=0.88 ⁎ r=0.87 ⁎ r=0.86 ⁎
r=0.52 ⁎ r=0.60 ⁎ r=0.59 ⁎
r=0.89 ⁎⁎ r=0.89 ⁎⁎ r=0.89 ⁎⁎
r=0.88 ⁎ r=0.91 ⁎⁎ r=0.90 ⁎⁎
r=0.87 ⁎ r=0.86 ⁎ r=0.88 ⁎
r=0.67 ⁎ r=0.72 ⁎ r=0.72 ⁎
r=0.78 ⁎⁎ r=0.78 ⁎⁎ r=0.77 ⁎⁎
r=0.71 ⁎ r=0.72 ⁎ r=0.70 ⁎
r=0.87 ⁎ r=0.88 ⁎ r=0.81 ⁎
ce; CFDR: cystic fibrosis-related diabetes, ISR; Insulin secretion rate; IVGTT:
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fasting insulin [27]. Therefore, surrogate estimates of β-cell
function may not be robust in situations with impaired β-cell
function, such as CF patients. In contrast to the HOMA-β cell,
both OGTT-derived indices included early insulin secretion time
points and correlated significantly with the IVGTT. Thus, in CF
patients, indices derived from the OGTTmay better reflect insulin
secretion dynamics than indices derived from fasting values.
Since the CF population requires an OGTT at regular interval to
screen for CFRD [1,2], insulin secretion could be easily added at
this time. However, we investigated a relatively small number of
newly diagnosed CFRD subjects. Accordingly, whether the
results are applicable to the whole spectrum of CF diabetic
patients remains to be investigated.
In summary, we present data demonstrating that early insulin
secretion indices derived from the OGTT are acceptable
surrogates to evaluate first-phase insulin secretion measured
by IVGTT and thus are appropriate for epidemiological and
physiological studies in the CF population.
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